The Reality of Pixantrone in Real Life.

Likewise, the cardiac tolerability of pixantrone in anthracycline-pretreated patients shows compelling evidence against pixantrone causing anthracycline-like cardiotoxicity or precipitating subclinical cardiotoxicity induced by prior anthracycline treatment. Relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is a challenging and poor-prognosis clinical setting. Only 3 patients developed grade IV toxicity causing treatment discontinuation, the grade III toxicities were consistent with the known characteristics of pixantrone, and only 1 case of mild cardiotoxicity was reported [[2]]. [Extracted from the article]